• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Hypertrophic cardiomyopathy is a myocardial disease defined by an increased left
ventricular wall thickness not solely explained by abnormal loading conditions. It is often …

Pediatric cardiomyopathies (CMs) and electrical diseases constitute a heterogeneous
spectrum of disorders distinguished by structural and electrical abnormalities in the heart …

Importance The ability to predict sudden cardiac death (SCD) in children and adolescents
with hypertrophic cardiomyopathy (HCM) is currently inadequate. Late gadolinium …

Syncopal events in patients with hypertrophic cardiomyopathy (HCM) are of concern as they
are a vital consideration in algorithms for risk stratification for sudden cardiac death (SCD) …

Sudden cardiac death is the most common mode of death during childhood and
adolescence in hypertrophic cardiomyopathy, and identifying those individuals at highest …

Aims Echocardiographic characteristics to distinguish physiological left ventricular (LV)
hypertrophy from pathology are warranted in early adolescent athletes. This study aimed to …

Sudden cardiac death (SCD) is associated with nonsustained ventricular tachycardia
(NSVT) in patients with hypertrophic cardiomyopathy (HCM). Recently, differences regarding …

Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality in
children. While the aetiology is heterogeneous, most cases are caused by variants in the …

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is defined clinically by pathological
left ventricular hypertrophy. We have previously developed a plasma proteomics biomarker …